Predicting disease progression in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): An analysis from the phase 3 SPARTAN trial.

被引：0

作者：

Small, Eric Jay

Saad, Fred

Rathkopf, Dana E.

Hadaschik, Boris A.

Chowdhury, Simon

Yu, Margaret K.

Lopez-Gitlitz, Angela

Rooney, Oliver Brendan

Shu, Youyi

Darif, Mohamed

Smith, Matthew Raymond

机构：

[1] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[2] Univ Montreal, Ctr Hosp Univ Montreal CRCHUM, Montreal, PQ, Canada

[3] Mem Sloan Kettering Canc Ctr, New York, NY USA

[4] Weill Cornell Med Coll, New York, NY USA

[5] Univ Duisburg Essen, Essen, Germany

[6] Guys Kings & St Thomas Hosp, London, England

[7] Janssen Res & Dev, Los Angeles, CA USA

[8] Janssen Res & Dev, High Wycombe, Bucks, England

[9] Janssen Res & Dev, Collegeville, PA USA

[10] Janssen Res & Dev, San Diego, CA USA

[11] Massachusetts Gen Hosp Canc Ctr, Boston, MA USA

[12] Harvard Med Sch, Boston, MA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.5034

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5034

引用

页数：2

共 50 条

[1] Relationship of time to metastasis (TTM) and site of metastases in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Results from the phase 3 SPARTAN trial.
Smith, Matthew Raymond
Saad, Fred
Rathkopf, Dana E.
Hadaschik, Boris A.
Chowdhury, Simon
Yu, Margaret K.
Lopez-Gitlitz, Angela
Rooney, Oliver Brendan
Darif, Mohamed
Small, Eric Jay
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[2] Identifying molecular determinants of response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the SPARTAN trial.
Feng, Felix Y.
Thomas, Shibu
Gormley, Michael
Lopez-Gitlitz, Angela
Yu, Margaret K.
Cheng, Shinta
Ricci, Deborah S.
Rooney, Oliver Brendan
Mainwaring, Paul N.
Olmos, David
Saad, Fred
Chowdhury, Simon
Hadaschik, Boris A.
Fishbane, Nicholas
Davicioni, Elai
Liu, Yang
Small, Eric Jay
Smith, Matthew Raymond
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[3] Efficacy and safety of apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from SPARTAN: Asian subpopulation
Mainwaring, P.
Small, E.
Uemura, H.
Lee, J. Y.
Pang, S-T.
Marx, G.
Kwon, T. G.
Satoh, T.
Bhaumik, A.
Cheng, S.
Londhe, A.
Lopez-Gitlitz, A.
Smith, M.
ANNALS OF ONCOLOGY, 2018, 29 : 68 - 68
[4] Apalutamide (APA) and Overall Survival (OS) in Patients (PTS) with Nonmetastatic Castration-Resistant Prostate Cancer (NMCRPC): Updated Results from The Phase 3 Spartan Study
Hadaschik, Boris A.
Smith, Matthew R.
Saad, Fred
Chowdhury, Simon
Oudards, Stephane
Graff, Julie N.
Olmos, David
Mainwaring, Paul N.
Lee, Ji Youl
Uemura, Hiroji
De Porre, Peter
Smith, Andressa
Zhang, Ke
Lopez-Gitlitz, Angela
Small, Eric J.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 71 - 71
[5] Androgen receptor (AR) anomalies and efficacy of apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the phase 3 SPARTAN study
Smith, Matthew R.
Thomas, Shibu
Chowdhury, Simon
Olmos, David
Li, Jinhui
Mainwaring, Paul N.
Oudard, Stephane
Feng, Felix Y.
Gormley, Michael
Ricci, Deborah S.
Rooney, Brendan
Lopez-Gitlitz, Angela
Yu, Margaret K.
Small, Eric J.
CANCER RESEARCH, 2018, 78 (13)
[6] Identifying molecular determinants of response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the SPARTAN study
Feng, Felix
Thomas, Shibu
Gormley, Michael
Lopez-Gitlitz, Angela
Yu, Margaret K.
Cheng, Shinta
Ricci, Deborah S.
Rooney, Brendan
Mainwaring, Paul N.
Olmos, David
Saad, Fred
Chowdhury, Simon
Hadaschik, Boris
Fishbane, Nick
Davicioni, Elai
Liu, Yang
Small, Eric J.
Smith, Matthew R.
CANCER RESEARCH, 2019, 79 (13)
[7] Androgen Receptor (AR) anomalies and efficacy of apalutamide in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the phase 3 SPARTAN study
Mainwaring, Paul N.
Smith, Matthew R.
Thomas, Shibu
Chowdhury, Simon
Olmos, David
Li, Jinhui
Oudard, Siephane
Feng, Felix Y.
Gormley, Michael
Ricci, Deborah S.
Rooney, Brendan
Lopez-Gitlitz, Angela
Yu, Margaret K.
Small, Eric J.
BJU INTERNATIONAL, 2018, 122 : 6 - 7
[8] PROSTATE-SPECIFIC ANTIGEN (PSA) OUTCOMES IN PATIENTS (PTS) WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) TREATED WITH APALUTAMIDE (APA): RESULTS FROM PHASE 3 SPARTAN STUDY
Small, Eric J.
Lee, Ji Youl
Lopez-Gitlitz, Angela
Saad, Fred
Rooney, Brendan
Hadaschik, Boris A.
Uemura, Hiroji
Shu, Youyi
Yu, Margaret
Smith, Matthew R.
JOURNAL OF UROLOGY, 2018, 199 (04): : E232 - E232
[9] Apalutamide (APA) and overall survival (OS) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Updated results from the phase III SPARTAN study
Smith, M. R.
Saad, F.
Chowdhury, S.
Oudard, S.
Hadaschik, B. A.
Graff, J. N.
Olmos, D.
Mainwaring, P. N.
Lee, J. Y.
Uemura, H.
De Porre, P.
Smith, A.
Zhang, K.
Lopez-Gitlitz, A.
Small, E. J.
ANNALS OF ONCOLOGY, 2019, 30 : 325 - 325
[10] RESPONSE TO APALUTAMIDE (APA) AMONG PATIENTS (PTS) WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) FROM SPARTAN BY DECIPHER GENOMIC CLASSIFIER (GC) SCORE
Saad, Fred
Thomas, Shibu
Feng, Felix Y.
Gormley, Michael
Lopez-Gitlitz, Angela
Yu, Margaret K.
Cheng, Shinta
Ricci, Deborah S.
Rooney, Oliver Brendan
Mainwaring, Paul N.
Olmos, David
Chowdhury, Simon
Hadaschik, Boris A.
Fishbane, Nick
Davicioni, Elai
Liu, Yang
Small, Eric J.
Smith, Matthew R.
JOURNAL OF UROLOGY, 2019, 201 (04): : E216 - E216

← 1 2 3 4 5 →